All In Biotech

Drug Trial Radar · NCT02030990

The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements

The Use of Intraoperative Mitomycin-C During Photorefractive Keratectomy and Its Effect on Postoperative Topical Steroid Requirements

Last checked: Nov 19, 2026Latest source record: Apr 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Aug 2014

Primary completion

Jan 2023

Study completion Jul 2023

Sponsor

Sponsor type
Federal agency
First posted
Jan 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (care provider)
Primary purpose
Prevention
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

1. Purpose To evaluate the use of mitomycin-C (MMC) as an intraoperative adjunct during photorefractive keratectomy (PRK), its effect on postoperative healing and its ability to reduce the postoperative topical steroid course after the surgery. 2. Research Design This is a single-center, prospective, comparative cohort study. 3. Hypothesis There will not be a significant difference in the refractive corrections amongst the treatment groups, 12 months after surgery. 4. Objectives The primary study objective is to compare the effect of intraoperative MMC and a postoperative short topical steroid taper of 3 weeks, intraoperative MMC and a rapid topical steroid taper of 1 week, and a more commonly accepted postoperative regimen of a 2 month long topical steroid taper without any intraoperative MMC. The primary endpoint evaluated will be objective estimates of refractive error (WaveScan WaveFront™ System) at 12 months post-surgery. Secondarily, the extent of haze formation will be evaluated objectively using densitometry maps generated by automated Scheimpflug imaging of the cornea (Pentacam®). Furthermore, the subjective vision from the patients' perspective will be evaluated by questionnaires.

Conditions

  • Corneal Opacity

Interventions

  • Mitomycin-CDrug

    0.01% applied to cornea with a sponge during PRK

  • Fluorometholone 1% topical ocular steroidDrug

    topical steroid drops applied to the cornea after PRK

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Refractive ErrorTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Navy Warfighter Refractive Surgery Center

    San Diego, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.